| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 41 (6), 1162-1171, 2023 | 3897 | 2023 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3341 | 2014 |
| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ... Annals of Oncology 29, iv192-iv237, 2018 | 2104* | 2018 |
| Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ... The lancet oncology 16 (6), 630-637, 2015 | 1449 | 2015 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1357 | 2012 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1242 | 2019 |
| Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial H Van Tinteren, OS Hoekstra, EF Smit, JHAM Van Den Bergh, ... The Lancet 359 (9315), 1388-1392, 2002 | 999 | 2002 |
| Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010 | 967 | 2010 |
| Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial D Planchard, EF Smit, HJM Groen, J Mazieres, B Besse, Å Helland, ... The Lancet Oncology 18 (10), 1307-1316, 2017 | 795 | 2017 |
| RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics MG Best, N Sol, I Kooi, J Tannous, BA Westerman, F Rustenburg, ... Cancer cell 28 (5), 666-676, 2015 | 756 | 2015 |
| Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer JP Van Meerbeeck, GWPM Kramer, PEY Van Schil, C Legrand, EF Smit, ... Journal of the National Cancer Institute 99 (6), 442-450, 2007 | 754 | 2007 |
| Pan-cancer whole-genome analyses of metastatic solid tumours P Priestley, J Baber, MP Lolkema, N Steeghs, E de Bruijn, C Shale, ... Nature 575 (7781), 210-216, 2019 | 668 | 2019 |
| Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids KK Dijkstra, CM Cattaneo, F Weeber, M Chalabi, J van de Haar, ... Cell 174 (6), 1586-1598. e12, 2018 | 660 | 2018 |
| Long‐term expanding human airway organoids for disease modeling N Sachs, A Papaspyropoulos, DD Zomer‐van Ommen, I Heo, L Böttinger, ... The EMBO journal 38 (4), e100300, 2019 | 624 | 2019 |
| Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non–small-cell lung cancer FJ Lagerwaard, CJA Haasbeek, EF Smit, BJ Slotman, S Senan International Journal of Radiation Oncology* Biology* Physics 70 (3), 685-692, 2008 | 603 | 2008 |
| Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ... Journal of Clinical Oncology 35 (22), 2490-2498, 2017 | 600 | 2017 |
| Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer J Wolf, T Seto, JY Han, N Reguart, EB Garon, HJM Groen, DSW Tan, ... New England Journal of Medicine 383 (10), 944-957, 2020 | 543 | 2020 |
| Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ... New England Journal of Medicine 383 (10), 931-943, 2020 | 509 | 2020 |
| 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up J Vansteenkiste, L Crino, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ... Annals of Oncology 25 (8), 1462-1474, 2014 | 488 | 2014 |
| Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial D Planchard, TM Kim, J Mazieres, E Quoix, G Riely, F Barlesi, PJ Souquet, ... The Lancet Oncology 17 (5), 642-650, 2016 | 430 | 2016 |
Pieter PostmusLUMC在 lumc.nl 的电子邮件经过验证
Pieter PostmusLUMC在 lumc.nl 的电子邮件经过验证